Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 6/20 | 0.54 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13244808 | 1.00 | KYNU (0.60) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL3188496 | 0.92 | CTSK (0.53) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL16862505 | 0.92 | CTSK (0.53) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL18857019 | 0.89 | CTSK (0.52) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL15381002 | 0.89 | ALDH1A1 (0.58) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL25636446 | 0.89 | ALDH1A1 (0.58) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL4425694 | 0.89 | PPARA (0.54) | ALDH1A1ALOX15CTSKCTSSCTSL | |
| SCHEMBL8299708 | 0.89 | PPARA (0.54) | ALDH1A1ALOX15CTSKCTSSCTSL | |
| SCHEMBL10535416 | 0.88 | KYNU (0.59) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL2519860 | 0.88 | KYNU (0.59) | KYNUALDH1A1ALOX15CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| CN-120091811-A | Integrin inhibitors and their use in combination with other agents | 普利安特治疗公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-4551204-A2 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | Pliant Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4525866-A1 | STABILIZATION OF INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4520329-A2 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4509512-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-118401521-A | Integrin inhibitors and their use in combination with other agents | 普利安特治疗公司 | 2024-07-26 | — | — | CN | disclosed |
| WO-2024155965-A2 | BIOMARKERS FOR USE IN INTEGRIN INHIBITOR THERAPY | PLIANT THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-20240122930-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | PLIANT THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| WO-2019173653-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019173653-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
| EP-2170814-B1 | ANTIBACTERIAL AGENTS | ACHAOGEN INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2662353-A2 | Antibacterial agents | Achaogen, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-20120065146-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2008154642-A2 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-5670684-A | CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-09-23 | — | — | US | disclosed |
| US-5576435-A | Process and intermediates for the preparation of excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-11-19 | — | — | US | disclosed |
| US-5470978-A | Process and intermediates for the preparation of excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0599518-A1 | Process and intermediates for the preparation of excitatory amino acide receptor antagonists | ELI LILLY AND COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | KYNU 3361/4885ALDH1A1 3476/4885ALOX15 2582/4885 |
| US-20120065146-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PLK2, PLK4 | KYNU 2622/4885ALDH1A1 4782/4885ALOX15 4071/4885 |
| US-20240122930-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | ITGB6, ITGA6, ITGAV | KYNU 4423/4885ALDH1A1 1094/4885ALOX15 1064/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | KYNU 3410/4885ALDH1A1 3834/4885ALOX15 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.